In this captivating episode, "Talking Ketamine" unpacks a groundbreaking paper by Sophie Holland that challenges our conventional understanding of ketamine, revealing it not as a single therapy, but a spectrum of modalities. The core tension lies in two distinct pathways: the high-dose "psychedelic" experience and the low-dose "psycholytic" approach. While chemically different from classic psychedelics, ketamine's subjective effects and its profound ability to induce neurogenesis and synaptogenesis—earning it the term "psychoplastogen" (think of it as rewiring and adding new rooms to your brain's house)—firmly establish its place in psychedelic medicine.

The psychedelic pathway, triggered by higher doses, induces intense altered states, often leading to ego dissolution and mystical experiences. This "reset button" effect is driven by a rapi ...